Acute Visual Loss
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Un-Explained Visual Loss Following Silicone Oil Removal
Roca et al. Int J Retin Vitr (2017) 3:26 DOI 10.1186/s40942-017-0079-6 International Journal of Retina and Vitreous ORIGINAL ARTICLE Open Access Un‑explained visual loss following silicone oil removal: results of the Pan American Collaborative Retina Study (PACORES) Group Jose A. Roca1, Lihteh Wu2* , Maria Berrocal3, Francisco Rodriguez4, Arturo Alezzandrini5, Gustavo Alvira6, Raul Velez‑Montoya7, Hugo Quiroz‑Mercado7, J. Fernando Arevalo8, Martín Serrano9, Luiz H. Lima10, Marta Figueroa11, Michel Farah10 and Giovanna Chico1 Abstract Purpose: To report the incidence and clinical features of patients that experienced un-explained visual loss following silicone oil (SO) removal. Methods: Multicenter retrospective study of patients that underwent SO removal during 2000–2012. Visual loss of 2 lines was considered signifcant. ≥ Results: A total of 324 eyes of 324 patients underwent SO removal during the study period. Forty two (13%) eyes sufered a signifcant visual loss following SO removal. Twenty three (7.1%) of these eyes lost vision secondary to known causes. In the remaining 19 (5.9%) eyes, the loss of vision was not explained by any other pathology. Eleven of these 19 patients (57.9%) were male. The mean age of this group was 49.2 16.4 years. Eyes that had an un-explained visual loss had a mean IOP while the eye was flled with SO of 19.6 6.9 mm± Hg. The length of time that the eye was flled with SO was 14.8 4.4 months. In comparison, eyes that± did not experience visual loss had a mean IOP of 14 7.3 mm Hg (p < 0.0002)± and a mean tamponade duration of 9.3 10.9 months (p < 0.0001). -
URGENT/EMERGENT When to Refer Financial Disclosure
URGENT/EMERGENT When to Refer Financial Disclosure Speaker, Amy Eston, M.D. has a financial interest/agreement or affiliation with Lansing Ophthalmology, where she is employed as a ophthalmologist. 58 yr old WF with 6 month history of decreased vision left eye. Ache behind the left eye for 2-3 months. Using husband’s contact lens solution made it feel better. Seen by two eye care professionals. Given glasses & told eye exam was normal. No past ocular history Medical history of depression Takes only aspirin and vitamins 20/20 OD 20/30 OS Eye Pressure 15 OD 16 OS – normal Dilated fundus exam & slit lamp were normal Pupillary exam was normal Extraocular movements were full Confrontation visual fields were full No red desaturation Color vision was slightly decreased but the same in both eyes Amsler grid testing was normal OCT disc – OD normal OS slight decreased RNFL OCT of the macula was normal Most common diagnoses: Dry Eye Optic Neuritis Treatment - copious amount of artificial tears. Return to recheck refraction Visual field testing Visual Field testing - Small defect in the right eye Large nasal defect in the left eye Visual Field - Right Hemianopsia. MRI which showed a subacute parietal and occipital lobe infarct. ANISOCORIA Size of the Pupil Constrictor muscles innervated by the Parasympathetic system & Dilating muscles innervated by the Sympathetic system The Sympathetic System Begins in the hypothalamus, travels through the brainstem. Then through the upper chest, up through the neck and to the eye. The Sympathetic System innervates Mueller’s muscle which helps to elevate the upper eyelid. -
Fluids Hypertension Syndromes: Migraines, Headaches, Normal Tension Glaucoma, Benign Intracranial Hypertension, Caffeine Intolerance
Fluids Hypertension Syndromes – Dr. Leonardo Izecksohn – page 1 Fluids Hypertension Syndromes: Migraines, Headaches, Normal Tension Glaucoma, Benign Intracranial Hypertension, Caffeine Intolerance. Etiologies, Pathophysiologies and Cure. Author: Leonardo Izecksohn. Medical Doctor, Ophthalmologist, Master of Public Health. We have no financial interest on any medicament, device, or technique described in this e-book. We authorize the free copy and distribution of this e-book for educational purposes. The 1st. edition was written at the year 1996, with 2 pages. There are other editions spread at the Internet. This is the enlarged and revised edition 65-f, updated on May 24, 2016. ISBN 978-85-906664-1-7 DOI: 10.13140/2.1.3074.5602 www.izecksohn.com/leonardo/ [email protected] Fluids Hypertension Syndromes – Dr. Leonardo Izecksohn – page 2 Abstract A – Migraines, Headaches and Fluids Hypertension Syndromes – What are they? - Answer: Migraines and most primary headaches are the aches of the pressure increase in the fluids: - Intraocular Aqueous Humor, - Intracranial Cerebrospinal Fluid, and - Inner ear’s Perilymph and Endolymph. We denominate the fluids’ pressure rises and their consequent migraines, signs, symptoms and sick- nesses as the Fluids Hypertension Syndromes. Migraines and headaches are not sicknesses: they are symptoms of the sicknesses. B – How many Fluids Hypertension Syndromes do exist? - Answer: There are three Fluids Hypertension Syndromes: 1- Ocular, due to raises of the intraocular Aqueous Humor pressure. 2- Cerebrospinal, due to raises of the intracranial Cerebrospinal Fluid pressure. 3- Inner Ears, due to raises of the inner ears' Perilymph and Endolymph pressures. Each patient can present one, two, or all the three Fluids Hypertension Syndromes in the same time. -
Taking the Mystery out of Abnormal Pupils
Taking the mystery out of abnormal pupils No financial disclosures Course Title: Taking the mystery out [email protected] of abnormal pupils Lecturer: Brad Sutton, OD, FAAO Clinical Professor IU School of Optometry . •Review of Anatomy Iris anatomy Iris sphincter Iris dilator Parasympathetic pathway Sympathetic pathway Parasympathetic Pathway Parasympathetic Pathway Light stimulates the retina then impulse Four neuron arc travels with the ganglion cells through the Retina to the pretectal nucleus in the chiasm into the optic tracts. 80% go to the midbrain (1) LGN , 20% to the pretectal nuclei.They Pretectal nucleus to the EW nucleus (2) then hemidecussate and terminate at the EW nucleus EW nucleus to the ciliary ganglion (3) Ciliary ganglion to the iris sphincter with short ciliary nerves (4) 1 Points of Interest Sympathetic Pathway Within the second order neuron there are Three neuron arc 30 near response fibers for every light Posterior hypothalamus to ciliospinal response fiber. This allows for light - near center of Budge ( C8 - T2 ). (1) dissociation. Center of Budge to the superior cervical The third order neuron runs with cranial ganglion in the neck (2) nerve III from the brain stem to the ciliary Superior cervical ganglion to the dilator ganglion. Superficially located prior to the muscle (3) cavernous sinus. Points of Interest Second order neuron runs along the surface of the lung, can be affected by a Pancoast tumor Third order neuron runs with the carotid artery then with the ophthalmic division of cranial nerve V 2 APD Testing testing……………….AKA……… … APD / reverse APD Direct and consensual response Which is the abnormal pupil ? Very simple rule. -
Acute Hydrops Following Penetrating Keratoplasty in a Keratoconic Patient
Acute Hydrops following PK • Baradaran-Rafiee et al Iranian Journal of Ophthalmology • Volume 20 • Number 4 • 2008 Acute Hydrops following Penetrating Keratoplasty in a Keratoconic Patient Alireza Baradaran-Rafiee, MD1 • Manijeh Mahdavi, MD2 • Sepehr Feizi, MD3 Abstract Purpose: To report a case with history of penetrating keratoplasty (PK) for keratoconus that developed acute hydrops in the recipient and donor cornea Methods: A 46-year-old man, with history of bilateral keratoconus, who had undergone corneal transplantation in his left eye, presented with complaints of sudden visual reduction, photophobia, redness and pain of the left eye. Results: Review of his clinical course, slit-lamp biomicroscopy, laboratory evaluations including confocal microscopy and ultrasound biomicroscopy revealed acute hydrops in the graft. Second corneal transplantation was done for his left eye and pathologic examination confirmed the diagnosis. Conclusion: Acute hydrops can occur after PK in patients with keratoconus. Although this condition is not common, it should be considered as a differential diagnosis of graft rejection. Keywords: Acute Hydrops, Keratoconus, Corneal Transplantation Iranian Journal of Ophthalmology 2008;20(4):49-53 Introduction Keratoconus is a degenerative, One of the complications of advanced non-inflammatory disease of the cornea, with keratoconus is acute hydrops. Affected onset generally at puberty. It is progressive in patients suffer from acute visual loss with pain 20% of cases and can be treated by lamellar and photophobia. On slit-lamp examination, or penetrating keratoplasty (PK). Its incidence conjunctival hyperemia and diffuse corneal in general population is reported to be about edema with intrastromal cystic spaces are 1/2000.1 Changes in corneal collagen visible. -
Miotics in Closed-Angle Glaucoma
Brit. J. Ophthal. (I975) 59, 205 Br J Ophthalmol: first published as 10.1136/bjo.59.4.205 on 1 April 1975. Downloaded from Miotics in closed-angle glaucoma F. GANIAS AND R. MAPSTONE St. Paul's Eye Hospital, Liverpool The initial treatment of acute primary closed-angle Table i Dosage in Groups I, 2, and 3 glaucoma (CAG) is directed towards lowering intraocular pressure (IOP) to normal levels as Group Case no. Duration IOP Time rapidly as possible. To this end, aqueous inflow is (days) (mm. Hg) (hrs) reduced by a drug such as acetazolamide (Diamox), and aqueous outflow is increased via the trabecular I I 2 8 5 meshwork by opening the closed angle with miotics. 3 7 21 3 The use of miotics is of respectable lineage and hal- 5 '4 48 7 lowed by usage, but regimes vary from "intensive" 7 8 I4 5 9 I0 I8 6 (i.e. frequent) to "occasional" (i.e. infrequent) instilla- I I 2 12 6 tions. Finally, osmotic agents are used after a variable '3 5 20 6 interval of time if the IOP remains raised. Tlle pur- I5 '4 I8 6 pose of this paper is to investigate the value of '7 '4 i6 6 miotics in the initial treatment of CAG. I9 6 02 2 2 2 8 2I 5 Material and methods 4 20t 20 6 Twenty patients with acute primary closed-angle glau- 6 I i8 5 http://bjo.bmj.com/ coma were treated, alternately, in one of two ways 8 4 i8 5 detailed below: I0 6 I8 6 I2 I0 20 6 (I) Intravenous Diamox 500 mg. -
Drug Class Review Ophthalmic Cholinergic Agonists
Drug Class Review Ophthalmic Cholinergic Agonists 52:40.20 Miotics Acetylcholine (Miochol-E) Carbachol (Isopto Carbachol; Miostat) Pilocarpine (Isopto Carpine; Pilopine HS) Final Report November 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Glaucoma Therapies ................................................................................................. 5 Table 2. Summary of Agents .................................................................................................. 6 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Glaucoma Clinical Practice Guidelines ................................... 9 Pharmacology ............................................................................................................................... 10 Methods ....................................................................................................................................... -
Textbook of Ophthalmology, 5Th Edition
Textbook of Ophthalmology Textbook of Ophthalmology 5th Edition HV Nema Former Professor and Head Department of Ophthalmology Institute of Medical Sciences Banaras Hindu University Varanasi India Nitin Nema MS Dip NB Assistant Professor Department of Ophthalmology Sri Aurobindo Institute of Medical Sciences Indore India ® JAYPEE BROTHERS MEDICAL PUBLISHERS (P) LTD. New Delhi • Ahmedabad • Bengaluru • Chennai Hyderabad • Kochi • Kolkata • Lucknow • Mumbai • Nagpur Published by Jitendar P Vij Jaypee Brothers Medical Publishers (P) Ltd B-3 EMCA House, 23/23B Ansari Road, Daryaganj, New Delhi 110 002 I ndia Phones: +91-11-23272143, +91-11-23272703, +91-11-23282021, +91-11-23245672 Rel: +91-11-32558559 Fax: +91-11-23276490 +91-11-23245683 e-mail: [email protected], Visit our website: www.jaypeebrothers.com Branches 2/B, Akruti Society, Jodhpur Gam Road Satellite Ahmedabad 380 015, Phones: +91-79-26926233, Rel: +91-79-32988717 Fax: +91-79-26927094, e-mail: [email protected] 202 Batavia Chambers, 8 Kumara Krupa Road, Kumara Park East Bengaluru 560 001, Phones: +91-80-22285971, +91-80-22382956, 91-80-22372664 Rel: +91-80-32714073, Fax: +91-80-22281761 e-mail: [email protected] 282 IIIrd Floor, Khaleel Shirazi Estate, Fountain Plaza, Pantheon Road Chennai 600 008, Phones: +91-44-28193265, +91-44-28194897 Rel: +91-44-32972089, Fax: +91-44-28193231, e-mail: [email protected] 4-2-1067/1-3, 1st Floor, Balaji Building, Ramkote Cross Road Hyderabad 500 095, Phones: +91-40-66610020, +91-40-24758498 Rel:+91-40-32940929 Fax:+91-40-24758499, e-mail: [email protected] No. 41/3098, B & B1, Kuruvi Building, St. -
Red Spot • Important Is the Time Period from the Event • Therapy Is Reasonable If the Patient Is Treated Within the First 6 Hours
ACUTE VISUAL LOSS KAROLÍNA SKORKOVSKÁ VISUAL LOSS • CENTRAL RETINAL ARTERY OCCLUSION • CENTRAL RETINAL VEIN OCCLUSION • RETINAL DETACHMENT • VITREOUS HAEMORRHAGE • OPTIC NEURITIS • AION VISUAL LOSS - PATIENT´S HISTORY • UNILATERAL / BILATERAL • SUDDEN / SLOWLY PROGRESSIVE • PAIN • COMPLAINTS (FOGGY VISION, FLOATERS, CURTAIN…) • OTHER SYMPTOMS (FEVER, WEIGHT LOSS, REFRACTIVE CHANGE, …) CATARACT • SLOWLY PROGRESSIVE VISUAL LOSS • FOGGY VISION • CHANGE IN REFRACTIVE ERROR (INDEX MYOPIA) • CATARACT VISIBLE ON SLIT LAMP • THERAPY: CATARACT EXTRACTION RETINAL ARTERY OCCLUSION • SUDDEN, UNILATERAL, PAINLESS LOSS OF VISION • VISUAL ACUITY MAY BE „NO LIGHT PERCEPTION“ • BRANCH / CENTRAL RETINAL ARTERY OCCLUSION • RETINAL ISCHEMIA WITH CHERRY RED SPOT • IMPORTANT IS THE TIME PERIOD FROM THE EVENT • THERAPY IS REASONABLE IF THE PATIENT IS TREATED WITHIN THE FIRST 6 HOURS RETINAL ARTERY OCCLUSION - COMPLICATIONS • POOR PROGNOSIS • PERMANENT LOSS OF VISION • OPTIC DISC ATROPHY • NEOVASCULARISATION GLAUCOMA RETINAL ARTERY OCCLUSION - THERAPY • LOWERING OF INTRAOCULAR PRESSURE • RETROBULBAR INJECTION OF VASODILATORS • PARACENTHESIS • SYSTEMIC TROMBOLYSIS (DEPARTMENT OF INTERNAL MEDICINE) • CHECK-UP OF RISK FACTORS OF ISCHEMIA / TROMBOSIS RETINAL VEIN OCCLUSION • SUDDEN, PAINLESS, UNILATERAL VISUAL LOSS • VISUAL ACUITY USUALLY NOT AS MUCH AFFECTED AS IN CRAO • BRANCH / CENTRAL RETINAL VEIN OCCLUSION • OFTEN CARDIOVASCULAR RISK FACTORS (HYPERTENSION, DIABETES, HYPERLIPIDEMIA, ISCHEMIC HEART DISEASE,…) • RETINAL HAEMORHAGES, OPTIC NERVE HEAD OEDEMA, RETINAL -
A Review of Central Retinal Artery Occlusion: Clinical Presentation And
Eye (2013) 27, 688–697 & 2013 Macmillan Publishers Limited All rights reserved 0950-222X/13 www.nature.com/eye 1 2 1 2 REVIEW A review of central DD Varma , S Cugati , AW Lee and CS Chen retinal artery occlusion: clinical presentation and management Abstract Central retinal artery occlusion (CRAO) is an that in turn place an individual at risk of future ophthalmic emergency and the ocular ana- cerebral stroke and ischaemic heart disease. logue of cerebral stroke. Best evidence reflects Although analogous to a cerebral stroke, there that over three-quarters of patients suffer is currently no guideline-endorsed evidence for profound acute visual loss with a visual acuity treatment. Current options for therapy include of 20/400 or worse. This results in a reduced the so-called ‘standard’ therapies, such as functional capacity and quality of life. There is sublingual isosorbide dinitrate, systemic also an increased risk of subsequent cerebral pentoxifylline or inhalation of a carbogen, stroke and ischaemic heart disease. There are hyperbaric oxygen, ocular massage, globe no current guideline-endorsed therapies, compression, intravenous acetazolamide and although the use of tissue plasminogen acti- mannitol, anterior chamber paracentesis, and vator (tPA) has been investigated in two methylprednisolone. None of these therapies randomized controlled trials. This review will has been shown to be better than placebo.5 describe the pathophysiology, epidemiology, There has been recent interest in the use of and clinical features of CRAO, and discuss tissue plasminogen activator (tPA) with two current and future treatments, including the recent randomized controlled trials on the 1Flinders Comprehensive use of tPA in further clinical trials. -
Mydriasis Associated with Local Dysfunction of Parasympathetic Nerves in Two Dogs
NOTE Internal Medicine Mydriasis Associated with Local Dysfunction of Parasympathetic Nerves in Two Dogs Teppei KANDA1), Kazuhiro TSUJI1), Keiko HIYAMA2), Takeshi TSUKA1), Saburo MINAMI1), Yoshiaki HIKASA1), Toshinori FURUKAWA3) and Yoshiharu OKAMOTO1)* 1)Department of Veterinary Medicine, Faculty of Agriculture, Tottori University, 4–101, Koyama-minami, Tottori 680–8553, 2)Takamori Animal Hospital, 3706–2, Agarimichi, Sakaiminato, Tottori 684–0033 and 3)Department of Comparative Animal Science, College of Life Science, Kurashiki University of Science and the Arts, 2640, Tsurajima-nishinoura, Kurashiki, Okayama 712–8505, Japan. (Received 13 August 2009/Accepted 16 November 2009/Published online in J-STAGE 9 December 2009) ABSTRACT. In clinical practice, photophobia resulting from persistent mydriasis may be associated with dysfunction of ocular parasympa- thetic nerves or primary iris lesions. We encountered a 5-year-old Miniature Dachshund and a 7-year-old Shih Tzu with mydriasis, abnormal pupillary light reflexes, and photophobia. Except for sustained mydriasis and photophobia, no abnormalities were detected on general physical examination or ocular examination of either dog. We performed pharmacological examinations using 0.1% and 2% pilo- carpine to evaluate and diagnose parasympathetic denervation of the affected pupillary sphincter muscles. On the basis of the results, we diagnosed a pupillary abnormality due to parasympathetic dysfunction and not to overt primary iris lesions. The test revealed that neuroanatomic localization of the lesion was postciliary ganglionic in the first dog. KEY WORDS: autonomic nervous system, canine, mydriasis, ophthalmology, tonic pupil. J. Vet. Med. Sci. 72(3): 387–389, 2010 Mydriasis and miosis are normal physiological reactions and we report herein the clinical features, diagnosis, and that allow the eye to adjust to the level of incoming light. -
COMPLEMENTARY THERAPY ASSESSMENT VISUAL TRAINING for REFRACTIVE ERRORS August 2013
COMPLEMENTARY THERAPY ASSESSMENT VISUAL TRAINING FOR REFRACTIVE ERRORS August 2013 SUMMARY DESCRIPTION OF VISUAL TRAINING Vision training consists of a variety of programs designed to enhance visual efficiency and processing. Vision training, or orthoptics, typically addresses how well both eyes work together. Eye exercises may include, muscle relaxation techniques, biofeedback, eye patches, eye massages, the use of under-corrected prescription lenses, and/or nutritional supplements. Training is most often provided by an optometrist. BENEFITS One randomized controlled trial (RCT) of biofeedback training for control of accommodation for myopia reported no statistically significant benefits from training (Level I evidence). Another RCT (2013), which investigated vision training modalities to evaluate changes in peripheral refraction profiles in myopes, also found no evidence of benefits (Level 1 evidence). In other studies undertaken over the last 60 years, an improvement in subjective visual acuity (VA) in myopes with no corresponding improvement in objective VA has been reported (Level II/III evidence). RISKS The only risk attributable to visual training is financial. Most health insurers do not cover visual training programs. At the start of treatment, the optometrist should provide a reasonable estimate of what improvement to expect and how long it will take. CONCLUSIONS There is Level I evidence that visual training for control of accommodation has no effect on myopia. In other studies (Level II/III evidence), an improvement in subjective VA for patients with myopia that have undertaken visual training has been shown, but no corresponding physiological cause for the improvement has been demonstrated. It is postulated that the improvements in myopic patients noted in these studies were due to improvements in interpreting blurred images, changes in mood or motivation, creation of an artificial contact lens by tear film changes, or a pinhole effect from miosis of the pupil.